1-3 of 3
Xiang Qin, PhD
Close
Sort by
Journal Articles

Long-Term Safety in a Phase 1 Study of Siltuximab (CNTO 328), an Anti-Interleukin-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease,

Razelle Kurzrock, MD, Peter M. Voorhees, MD, Corey Casper, MD, Richard R. Furman, MD, Luis Fayad, MD, Sagar Lonial, MD, Hossein Borghaei, DO, Sundar Jagannath, MD, Lubomir Sokol, MD, PhD, Saad Usmani, MD, FACP, Helgi van de Velde, MD, PhD, Xiang Qin, PhD, Ming Qi, MD, PhD, Mark J. Cornfeld, MD, MPH, Frits van Rhee, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 3959.
https://doi.org/10.1182/blood.V118.21.3959.3959
Published: 2011
Journal Articles

A Phase 2 Multicenter Study of Siltuximab, An Anti-IL-6 Monoclonal Antibody, in Patients with Relapsed or Refractory Multiple Myeloma,

Peter M. Voorhees, MD, Robert F Manges, MD, Pieter Sonneveld, MD, PhD, Sundar Jagannath, MD, George Somlo, MD, Amrita Krishnan, MD, Suzanne Lentzsch, MD, PhD, Richard C Frank, MD, Sonja Zweegman, MD, PhD, P.W. Wijermans, MD, PhD, Britte Rijnbeek, Xiang Qin, PhD, Mark J. Cornfeld, MD, MPH, Hong Xie, MD, MS, MBA, Sheeba K. Thomas, MD
Journal: Blood
Blood (2011) 118 (21): 3971.
https://doi.org/10.1182/blood.V118.21.3971.3971
Published: 2011
Journal Articles

A Phase I Study of CNTO 328, An Anti-Interleukin-6 Monoclonal Antibody in Patients with B-Cell Non-Hodgkin’s Lymphoma, Multiple Myeloma, or Castleman’s Disease.

Razelle Kurzrock, MD, Luis Fayad, Peter Voorhees, MD, Richard R Furman, MD, Sagar Lonial, MD, Hossein Borghaei, DO, MS, Sundar Jagannath, MD, Lubomir Sokol, MD, PhD, Mark Cornfeld, MD, MPH, Ming Qi, MD, PhD, Trina Jiao, MS, Jennifer Herring, RN, Xiang Qin, PhD, Frits van Rhee, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 1009.
https://doi.org/10.1182/blood.V112.11.1009.1009
Published: 2008